Only 2 people have added BeiGene to their MarketBeat watchlist in the last 30 days. Only 1 people have searched for BGNE on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days. Upgrade to MarketBeat All Access to add more stocks to your watchlist. If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. could be a great choice.

Certain https://1investing.in/ Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.

BeiGene has a short interest ratio („days to cover“) of 8.9. BeiGene Ltd. said Monday it had entered an agreement with Swiss drug company Novartis Pharma AG to develop its investigational TIGIT inhibitor ociperlimab in North America, Europe, and Japan and to market five Novartis o… Highlights important summary options statistics to provide a forward looking indication of investors‘ sentiment. The Barchart Technical Opinion rating is a 64% Buy with a Average short term outlook on maintaining the current direction. Intellia Therapeutics reports loss for fourth-quarter 2022, in line with estimates. Prelude Therapeutics and BeiGene collaborate on clinical trials to evaluate PRT2527 with zanubrutinib for treating hematologic cancer patients.

Information is provided ‚as-is‘ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. One share of BGNE stock can currently be purchased for approximately $238.45.

BeiGene to Present at the J.P. Morgan 41st Annual Healthcare Conference

U.S. Treasuries (“T-Bill“) investing services on the Public Platform are offered by Jiko Securities, Inc. (“JSI”), a registered broker-dealer and member of FINRA & SIPC. See JSI’s FINRA BrokerCheck and Form CRS for further information. When you enable T-Bill investing on the Public platform, you open a separate brokerage account with JSI (the “Treasury Account“). What analysts recommend for BGNE stock, on a scale from 1 to 5.

The company’s clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising… On Immunocore’s Q4 earnings call, investors will likely focus on the sales figure of Kimmtrak – its first-line treatment for metastatic uveal melanoma – and updates on its pipeline candidates.

Insider Activity at BeiGene

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… Brokerage services for alternative assets available on Public are offered by Dalmore Group, LLC (“Dalmore”), member of FINRA & SIPC. “Alternative assets,” as the term is used at Public, are equity securities that have been issued pursuant to Regulation A of the Securities Act of (“Regulation A”).

• Investing.com – BeiGene ADS reported on Wednesday third quarter erl ||earnings that missed analysts‘ forecasts and revenue that topped expectations.
• Market cap, also known as market capitalization, is the total market value of a company.
• Morgan Stanley cut their target price on shares of BeiGene from $325.00 to $321.00 and set an “overweight” rating for the company in a research report on Tuesday, February 28th.
• This is a decrease of -91% compared to the previous 30 days.

As of April 05, 2023, Beigene Ltd has a weighted four-quarter relative price strength of 2.70%, which translates to a Momentum Score of 73 and is considered to be Strong. Since inception in 1978, the nonprofit AAII has helped over 2 million individuals build their investment wealth through programs of education, publications, software and grassroots meetings. Get stock recommendations, portfolio guidance, and more from The Motley Fool’s premium services. The Motley Fool has positions in and recommends Goldman Sachs Group. A collaboration deal helped send the Chinese biotech stock higher. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.

Alibaba and Other Chinese Stocks Got Crushed Thursday. Here’s Why.

See Jiko U.S. Treasuries Risk Disclosures for further details. Discuss news and analysts‘ price predictions with the investor community. BeiGene reported an EPS of -$4.29 in its last earnings report, beating expectations of -$4.635. Following the earnings report the stock price went up 0.814%. 5 Best Healthcare Stocks to Invest in Now, According to Analysts The volatile stock market scenario makes it prudent to invest in defensive investment options such as healthcare stocks…. Unfortunately, Beigene Ltd ’s P/E ratio is not significant enough to use for stock price evaluation.

Guggenheim reissued a „buy“ how many nations in europe and issued a $350.00 target price on shares of BeiGene in a research note on Tuesday, February 28th. StockNews.com started coverage on BeiGene in a report on Thursday, March 16th. Finally, Daiwa Capital Markets began coverage on BeiGene in a report on Wednesday, January 11th. They set a „buy“ rating and a $308.00 price objective on the stock.

The Company has in-licensed the rights to distribute 13 approved medicines for the China market. A number of equities analysts have issued reports on the stock. Morgan Stanley cut their target price on shares of BeiGene from $325.00 to $321.00 and set an „overweight“ rating for the company in a research report on Tuesday, February 28th. Cowen upped their price objective on BeiGene from $213.00 to $262.00 and gave the company an „outperform“ rating in a research report on Tuesday, February 28th.

This ratio is expressed as a percentage and helps investors understand a company’s momentum as well as its value. You can use relative price strength to select investments that have been outperforming the market or a specific benchmark. One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 05, 2023, there were 0 analysts who downgraded Beigene Ltd ’s stock and 1 analyst who upgraded over the last month. Rose 14.3% by late Thursday afternoon and closed the day 12.48% higher.

The Zacks Industry Rank assigns a rating to each of the 265 X Industries based on their average Zacks Rank. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‚V‘ for Value, ‚G‘ for Growth and ‚M‘ for Momentum), which combines the weighted average of the individual style scores into one score. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.

One analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of „Moderate Buy“ and a consensus target price of $292.86. Morgan Stanley cut their target price on shares of BeiGene from $325.00 to $321.00 and set an “overweight” rating for the company in a research report on Tuesday, February 28th. Cowen upped their price objective on BeiGene from $213.00 to $262.00 and gave the company an “outperform” rating in a research report on Tuesday, February 28th. Guggenheim reissued a “buy” rating and issued a $350.00 target price on shares of BeiGene in a research note on Tuesday, February 28th.

A stock’s beta measures how closely tied its price movements have been to the performance of the overall market. Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. There may be delays, omissions, or inaccuracies in the Information. The technique has proven to be very useful for finding positive surprises.

During the month of April, Beigene Ltd ’s stock price has reached a high of $242.44 and a low of $210.32. The other risk for BeiGene is whether the stock might be delisted if U.S. regulators find the company hasn’t been forthcoming in its accounting practices, a common concern among Chinese companies. In the long term, however, the stock has potential, with more than 60 clinical programs in its pipeline.

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company’s employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend. Sign-up to receive the latest news and ratings for BeiGene and its competitors with MarketBeat’s FREE daily newsletter.

For example, a price above its moving average is generally considered an upward trend or a buy. The chart below shows how a company’s ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green. A number of other hedge funds have also recently added to or reduced their stakes in BGNE.